Home Blog

0 0

Patent Number: 8,852,570

Grant date: December 31, 1969
Priority date: July 14, 1997
Estimated expiration date: July 14, 2017
Inventor(s): Pittenger; Mark F. (Severna Park, MD), Gordon; Stephen L. (Columbia, MD), Mackay; Alastair Morgan (Timonium, MD), Martin; Bradley J. (Ellicott City, MD)
Assignee(s): Mesoblast International Sarl (CH)
External link: USPTO website

Abstract:

Disclosed is a method for producing cardiomyocytes in vivo by administering to the heart of an individual a cardiomyocyte producing amount of mesenchymal stem cells. These cells can be administered as a liquid injectable or as a preparation of cells in a matrix which is or becomes solid or semi-solid. The cells can be genetically modified to enhance myocardial differentiation and integration. Also disclosed is a method for replacing cells ex vivo in a heart valve for implantation.

0 0

Patent Number: 8,852,572

Grant date: December 31, 1969
Priority date: July 14, 1997
Estimated expiration date: July 14, 2017
Inventor(s): Pittenger; Mark F. (Severna Park, MD), Gordon; Stephen L. (Columbia, MD), Mackay; Alastair Morgan (Towson, MD)
Assignee(s): Mesoblast International Sarl (CH)
External link: USPTO website

Abstract:

Disclosed are compositions and methods for repairing and/or regenerating cardiac tissue by administering adult bone marrow-derived stem cells to an individual. These cells can be administered as a liquid injectible or as a preparation of cells in a matrix which is or becomes solid or semi-solid. The cells can be genetically modified to enhance myocardial differentiation and integration. Also disclosed is a method for replacing cells ex vivo in a heart valve for implantation.

0 0

Patent Number: 8,852,573

Grant date: December 31, 1969
Priority date: July 14, 1997
Estimated expiration date: July 14, 2017
Inventor(s): Pittenger; Mark F. (Severna Park, MD), Gordon; Stephen L. (Columbia, MD), Mackay; Alastair Morgan (Towson, MD)
Assignee(s): Mesoblast International Sarl (CH)
External link: USPTO website

Abstract:

Disclosed are compositions and methods for repairing and/or regenerating cardiac tissue by administering adult bone marrow-derived stem cells to an individual. These cells can be administered as a liquid injectible or as a preparation of cells in a matrix which is or becomes solid or semi-solid. The cells can be genetically modified to enhance myocardial differentiation and integration. Also disclosed is a method for replacing cells ex vivo in a heart valve for implantation.

0 0

Patent Number: 8,852,575

Grant date: December 31, 1969
Priority date: July 14, 1997
Estimated expiration date: July 14, 2017
Inventor(s): Pittenger; Mark F. (Severna Park, MD), Gordon; Stephen L. (Columbia, MD), Mackay; Alastair Morgan (Towson, MD)
Assignee(s): Mesoblast International Sarl (CH)
External link: USPTO website

Abstract:

Disclosed are compositions and methods for method of treating a subject having reduced cardiac function or cardiac disease by administering adult bone marrow-derived stem cells to an individual. In some embodiments, the subject is a myocardial infarction patient or congestive heart failure patient. These cells can be administered as a liquid injectable or as a preparation of cells in a matrix which is or becomes solid or semi-solid. The cells can be genetically modified to enhance myocardial differentiation and integration. Also disclosed is a method for replacing cells ex vivo in a heart valve for implantation.

0 0

Patent Number: 8,852,571

Grant date: December 31, 1969
Priority date: July 14, 1997
Estimated expiration date: July 14, 2017
Inventor(s): Pittenger; Mark F. (Severna Park, MD), Gordon; Stephen L. (Columbia, MD), Mackay; Alastair Morgan (Timonium, MD), Martin; Bradley J. (Ellicott City, MD)
Assignee(s): Mesoblast International Sarl (CH)
External link: USPTO website

Abstract:

Disclosed is a method for producing cardiomyocytes in vivo by administering to the heart of an individual a cardiomyocyte producing amount of mesenchymal stem cells. These cells can be administered as a liquid injectible or as a preparation of cells in a matrix which is or becomes solid or semi-solid. The cells can be genetically modified to enhance myocardial differentiation and integration. Also disclosed is a method for replacing cells ex vivo in a heart valve for implantation.

0 0

Patent Number: 8,893,995

Grant date: December 31, 1969
Priority date: November 08, 2011
Estimated expiration date: November 08, 2031
Inventor(s): Taghizadeh; Rouzbeh R. (Cambridge, MA), Meade; John (Mendon, MA)
Assignee(s): Auxocell Laboratories, Inc. (Cambridge, MA)
External link: USPTO website

Abstract:

The present invention efficiently and cost-effectively extracts and collects cells from a tissue. The inventors have discovered that the tissue can be effectively fragmented and the resulting cells can be purified using a system or kit with multiple components. An advantage of the present invention is that tissue processing takes place in a closed system such that sterility can be maintained throughout the process, even if certain components are removed during processing, for example through the use of valves, clamps, and heat seals. Furthermore, any or all of the steps can be automated or manually accomplished, according to the specific needs of the application or the user.

0 0

Patent Number: 8,852,574

Grant date: December 31, 1969
Priority date: July 14, 1997
Estimated expiration date: July 14, 2017
Inventor(s): Pittenger; Mark F. (Severna Park, MD), Gordon; Stephen L. (Columbia, MD), Mackay; Alastair Morgan (Towson, MD)
Assignee(s): Mesoblast International Sarl (CH)
External link: USPTO website

Abstract:

Disclosed are compositions and methods for repairing and/or regenerating cardiac tissue by administering adult bone marrow-derived stem cells to an individual. These cells can be administered as a liquid injectible or as a preparation of cells in a matrix which is or becomes solid or semi-solid. The cells can be genetically modified to enhance myocardial differentiation and integration. Also disclosed is a method for replacing cells ex vivo in a heart valve for implantation.

0 0

Patent Number: 8,853,377

Grant date: December 31, 1969
Priority date: July 14, 1997
Estimated expiration date: July 14, 2017
Inventor(s): Guild; Braydon Charles (Concord, MA), Heartlein; Michael (Boxborough, MA)
Assignee(s): Shire Human Genetic Therapies, Inc. (Lexington, MA)
External link: USPTO website

Abstract:

Compositions for modulating the expression of a protein in a target cell comprising at least one RNA molecule which comprises at least one modification conferring stability to the RNA, as well as related methods, are disclosed.

0 0

Patent Number: 8,852,938

Grant date: December 31, 1969
Priority date: July 14, 1997
Estimated expiration date: July 14, 2017
Inventor(s): Sun; DongMing (Piscataway, NJ), Young; Wise (New Brunswick, NJ)
Assignee(s): Rutgers, The State University of New Jersey (New Brunswick, NJ)
External link: USPTO website

Abstract:

The present invention provides methods for expanding human umbilical cord blood stem cells and methods for stimulating growth factor production by cord blood stem cells using an in vitro cell culture system comprising a lithium salt. The present invention also provides in vivo methods for enhancing the survival and growth of transplanted cord blood stem cells by treating the cells with a lithium salt prior to transplantation. In vivo methods for reducing rejection of transplanted cord blood stem cells by administering a lithium salt after transplantation are also provided.

0 0

Patent Number: 8,852,935

Grant date: December 31, 1969
Priority date: July 14, 1997
Estimated expiration date: July 14, 2017
Inventor(s): Sackstein; Robert (Sudbury, MA)
Assignee(s):
External link: USPTO website

Abstract:

Methods and compositions for modifying glycans (e.g., glycans expressed on the surface of live cells or cell particles) are provided herein.